Literature DB >> 21205805

Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia.

Kenneth L Subotnik1, Keith H Nuechterlein, Joseph Ventura, Michael J Gitlin, Stephen Marder, Jim Mintz, Gerhard S Hellemann, Leslie A Thornton, Indira R Singh.   

Abstract

OBJECTIVE: This study examined the effect of medication nonadherence on the return of positive symptoms among recent-onset schizophrenia patients.
METHOD: Three sets of operational criteria for medication nonadherence with differing levels of severity were compared for their ability to predict relapse. Explicit operational criteria are provided with the hope that they will be adopted by others. Psychotic symptoms were prospectively rated on a frequent basis, and systematic criteria were applied using a computer scoring program to identify periods of psychotic symptom return. In addition, a specialized statistical survival analysis method, optimal for examining risk periods and outcomes that can recur during the follow-up assessment, was used.
RESULTS: As hypothesized, medication nonadherence robustly predicted a return of psychotic symptoms during the early phase of schizophrenia (hazard ratios=3.7-28.5, depending on the severity of nonadherence).
CONCLUSIONS: Even brief periods of partial nonadherence lead to greater risk of relapse than what is commonly assumed. Patients in the early phase of schizophrenia should be cautioned about the possible consequences of partial or relatively brief periods of antipsychotic medication nonadherence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21205805      PMCID: PMC5069345          DOI: 10.1176/appi.ajp.2010.09010087

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  25 in total

1.  One year outcome in first episode schizophrenia. Predictors of relapse.

Authors:  Alp Uçok; Aslihan Polat; Sibel Cakir; Aysun Genç
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-18       Impact factor: 5.270

2.  Baseline neurocognitive deficits in the CATIE schizophrenia trial.

Authors:  Richard S E Keefe; Robert M Bilder; Philip D Harvey; Sonia M Davis; Barton W Palmer; James M Gold; Herbert Y Meltzer; Michael F Green; Del D Miller; Jose M Canive; Lawrence W Adler; Theo C Manschreck; Marvin Swartz; Robert Rosenheck; Diana O Perkins; Trina M Walker; T Scott Stroup; Joseph P McEvoy; Jeffrey A Lieberman
Journal:  Neuropsychopharmacology       Date:  2006-04-19       Impact factor: 7.853

3.  A prospective 3-year longitudinal study of cognitive predictors of relapse in first-episode schizophrenic patients.

Authors:  Eric Yu-Hai Chen; Christy Lai-Ming Hui; Eva Lai-Wah Dunn; May Yin-King Miao; Wai-Song Yeung; Chi-Keung Wong; Wah-Fat Chan; Wai-Nang Tang
Journal:  Schizophr Res       Date:  2005-09-01       Impact factor: 4.939

4.  Expressed emotion, affective style, lithium compliance, and relapse in recent onset mania.

Authors:  D J Miklowitz; M J Goldstein; K H Nuechterlein; K S Snyder; J A Doane
Journal:  Psychopharmacol Bull       Date:  1986

5.  Predictors of compliance with neuroleptic medication among inpatients with schizophrenia: a discriminant function analysis.

Authors:  G Donohoe; N Owens; C O'Donnell; T Burke; L Moore; A Tobin; E O'Callaghan
Journal:  Eur Psychiatry       Date:  2001-08       Impact factor: 5.361

6.  Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

Authors:  D Robinson; M G Woerner; J M Alvir; R Bilder; R Goldman; S Geisler; A Koreen; B Sheitman; M Chakos; D Mayerhoff; J A Lieberman
Journal:  Arch Gen Psychiatry       Date:  1999-03

7.  Awareness of illness in schizophrenia and outpatient treatment adherence.

Authors:  B J Cuffel; J Alford; E P Fischer; R R Owen
Journal:  J Nerv Ment Dis       Date:  1996-11       Impact factor: 2.254

8.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

9.  Neuropsychological prediction of treatment efficacy and one-year outcome in schizophrenia.

Authors:  R S Goldman; B N Axelrod; R Tandon; S C Ribeiro; K Craig; S Berent
Journal:  Psychopathology       Date:  1993       Impact factor: 1.944

10.  Individual placement and support for individuals with recent-onset schizophrenia: integrating supported education and supported employment.

Authors:  Keith H Nuechterlein; Kenneth L Subotnik; Luana R Turner; Joseph Ventura; Deborah R Becker; Robert E Drake
Journal:  Psychiatr Rehabil J       Date:  2008
View more
  38 in total

Review 1.  Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments.

Authors:  George Bartzokis
Journal:  Neuropharmacology       Date:  2012-01-28       Impact factor: 5.250

2.  Family burden predicts functional outcome in the early course of schizophrenia beyond psychiatric symptoms and baseline functioning.

Authors:  Nicole R DeTore; Joseph Ventura; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2018-07-07       Impact factor: 4.939

3.  Medication adherence in first episode psychosis: the role of pre-onset subthreshold symptoms.

Authors:  J-G Daneault; A Maraj; M Lepage; A Malla; N Schmitz; S N Iyer; R Joober; J L Shah
Journal:  Acta Psychiatr Scand       Date:  2019-04       Impact factor: 6.392

4.  Impact on intracortical myelination trajectory of long acting injection versus oral risperidone in first-episode schizophrenia.

Authors:  George Bartzokis; Po H Lu; Erika P Raven; Chetan P Amar; Nicole R Detore; Alexander J Couvrette; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2012-07-17       Impact factor: 4.939

5.  Applications of temporal kernel canonical correlation analysis in adherence studies.

Authors:  Majnu John; Todd Lencz; Janina Ferbinteanu; Juan A Gallego; Delbert G Robinson
Journal:  Stat Methods Med Res       Date:  2015-08-20       Impact factor: 3.021

6.  Community Health Workers: a Resource to Support Antipsychotic Medication Adherence.

Authors:  Caitlin G Allen; Michael A Sugarman; Ashley Wennerstrom
Journal:  J Behav Health Serv Res       Date:  2017-04       Impact factor: 1.505

7.  Enhancing return to work or school after a first episode of schizophrenia: the UCLA RCT of Individual Placement and Support and Workplace Fundamentals Module training.

Authors:  Keith H Nuechterlein; Kenneth L Subotnik; Joseph Ventura; Luana R Turner; Michael J Gitlin; Denise Gretchen-Doorly; Deborah R Becker; Robert E Drake; Charles J Wallace; Robert P Liberman
Journal:  Psychol Med       Date:  2019-01-04       Impact factor: 7.723

8.  Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.

Authors:  Joseph Ventura; Kenneth L Subotnik; Michael J Gitlin; Denise Gretchen-Doorly; Arielle Ered; Kathleen F Villa; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-12-08       Impact factor: 4.939

9.  Enhancing Cognitive Training Through Aerobic Exercise After a First Schizophrenia Episode: Theoretical Conception and Pilot Study.

Authors:  Keith H Nuechterlein; Joseph Ventura; Sarah C McEwen; Denise Gretchen-Doorly; Sophia Vinogradov; Kenneth L Subotnik
Journal:  Schizophr Bull       Date:  2016-07       Impact factor: 9.306

10.  The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.

Authors:  Julie A Kreyenbuhl; Deborah R Medoff; Joseph P McEvoy; Thomas E Smith; Ann L Hackman; Ilana R Nossel; Lisa B Dixon; Susan M Essock; Robert W Buchanan
Journal:  Psychiatr Serv       Date:  2016-07-01       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.